Literature DB >> 12919183

Allele and genotype frequency of CYP2C19 in a Tamilian population.

C Adithan1, N Gerard, S Vasu, J Rosemary, C H Shashindran, R Krishnamoorthy.   

Abstract

AIMS: To investigate the frequencies of CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles and CYP2C19 genotypes in a Tamilian population.
METHODS: The study was conducted in 112 unrelated healthy human volunteers. DNA was extracted from leucocytes and analyzed by the PCR-RFLP protocol. The PCR product was digested with restriction enzymes (SmaI and BamH1) and then separated electrophoretically using polyacrylamide gel.
RESULTS: The frequencies of the CYP2C19*1, *2 and *3 alleles were 0.598 [95% confidence interval (CI) 0.507, 0.689], 0.379 (95% CI, 0.350,0.407) and 0.022 (95% CI -0.005, 0.049), respectively. The distribution of CYP2C19*1/*1,*1/*2, *1/*3, *2/*2 and *2/*3 genotypes were 0.295 (95% CI, 0.210, 0.379), 0.580 (95% CI, 0.488, 0.671), 0.027 (95% CI -0.003, 0.057), 0.080 (95% CI 0.030, 0.130) and 0.018 (95% CI -0.006, 0.042), respectively.
CONCLUSIONS: The distribution of CYP2C19*1/*1 in the Tamilian population is lower than that in Caucasians, Africans and the North Indian population. The CYP2C19*1/*2 is significantly higher in Tamilians when compared with other populations. The CYP2C19*1/*3 allele, which was not reported in the North Indian and Caucasian populations has been identified in 2.7% of the Tamilian population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12919183      PMCID: PMC1884356          DOI: 10.1046/j.1365-2125.2003.01883.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.

Authors:  A S Aynacioglu; C Sachse; A Bozkurt; S Kortunay; M Nacak; T Schröder; S O Kayaalp; I Roots; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  1999-08       Impact factor: 6.875

2.  Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.

Authors:  S Sviri; S Shpizen; E Leitersdorf; M Levy; Y Caraco
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

3.  Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.

Authors:  Wichittra Tassaneeyakul; Arporn Tawalee; Wongwiwat Tassaneeyakul; Veerapol Kukongviriyapan; Joyce Blaisdell; Joyce A Goldstein; Dhanu Gaysornsiri
Journal:  Pharmacogenetics       Date:  2002-04

4.  CYP2C19 genetic mutations in North Indians.

Authors:  J K Lamba; R K Dhiman; K K Kohli
Journal:  Clin Pharmacol Ther       Date:  2000-09       Impact factor: 6.875

5.  Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.

Authors:  T Kubota; K Chiba; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Authors:  K Herrlin; A Y Massele; M Jande; C Alm; G Tybring; Y A Abdi; A Wennerholm; I Johansson; M L Dahl; L Bertilsson; L L Gustafsson
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

8.  Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.

Authors:  S M de Morais; J A Goldstein; H G Xie; S L Huang; Y Q Lu; H Xia; Z S Xiao; N Ile; H H Zhou
Journal:  Clin Pharmacol Ther       Date:  1995-10       Impact factor: 6.875

9.  Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.

Authors:  J A Goldstein; T Ishizaki; K Chiba; S M de Morais; D Bell; P M Krahn; D A Evans
Journal:  Pharmacogenetics       Date:  1997-02
  9 in total
  24 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  CYP3A phenotypes and genotypes in North Indians.

Authors:  Naushad Rais; Yogesh K Chawla; Krishan K Kohli
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

3.  The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians.

Authors:  J Rosemary; C Adithan; N Padmaja; C H Shashindran; N Gerard; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2005-01-21       Impact factor: 2.953

4.  Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population.

Authors:  Manu Jose; Jayanthi Mathaiyan; Shivanand Kattimani; Surendiran Adithan; Adithan Chandrasekaran
Journal:  Eur J Clin Pharmacol       Date:  2016-04-20       Impact factor: 2.953

5.  The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.

Authors:  Mehmet Seven; Bahadir Batar; Selin Unal; Gozde Yesil; Adnan Yuksel; Mehmet Guven
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

6.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

7.  A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.

Authors:  P C Rath; Sundar Chidambaram; Pallavi Rath; Byomakesh Dikshit; Sudhir Naik; Prashant K Sahoo; Brajraj Das; Mohanshankar Mahalingam; Lakshmipathi Khandrika; Jugnu Jain
Journal:  Indian Heart J       Date:  2015-04-27

Review 8.  Implementing genotype-guided antithrombotic therapy.

Authors:  Richard L Seip; Jorge Duconge; Gualberto Ruaño
Journal:  Future Cardiol       Date:  2010-05

9.  Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.

Authors:  Kannan Sridharan; Rachna Kataria; Drishti Tolani; Shital Bendkhale; Nithya J Gogtay; Urmila M Thatte
Journal:  Indian J Pharmacol       Date:  2016 Jul-Aug       Impact factor: 1.200

10.  Glutathione S-transferase M1 and T1 null genotype distribution in South Indians.

Authors:  A T Naveen; C Adithan; N Padmaja; C H Shashindran; B K Abraham; K Satyanarayanamoorthy; P Anitha; N Gerard; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.